Healthcare professional network Doximity (NYSE:DOCS) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 17.1% year on year to $138.3 million. On the other hand, next quarter’s revenue guidance of $139.5 million was less impressive, coming in 2.4% below analysts’ estimates. Its non-GAAP profit of $0.38 per share was 39.3% above analysts’ consensus estimates. Is now the time to buy Doximity? Find out in our full research report. Doximity (DOCS) Q1 CY2025 Highlights: Revenue: $138.3 million vs analyst estimates of $133.6 million (17.1% year-on-year growth, 3.5% beat) Adjusted EPS: $0.38 vs analyst estimates of $0.27 (39.3% beat) Adjusted Operating Income: $67.97 million vs analyst estimates of $63.08 million (49.1% margin, 7.8% beat) Management’s revenue guidance for the upcoming financial year 2026 is $625 million at the midpoint, missing analyst estimates by 2.3% and implying 9.6% growth (vs 19.7% in FY2025) EBITDA guidance for the upcoming financial year 2026 is $339 million at the midpoint, below analyst estimates of $348 million Operating Margin: 35.2%, in line with the same quarter last year Free Cash Flow Margin: 70.1%, up from 37.6% in the previous quarter Market Capitalization: $11.16 billion “We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue growth,” said Jeff Tangney, co-founder and CEO of Doximity. Company Overview Founded in 2010 and named for a combination of “docs” and “proximity”, Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Sales Growth A company’s long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last three years, Doximity grew its sales at a 18.4% compounded annual growth rate. Although this growth is acceptable on an absolute basis, it fell slightly short of our standards for the software sector, which enjoys a number of secular tailwinds. Luckily, there are other things to like about Doximity.Doximity Quarterly Revenue This quarter, Doximity reported year-on-year revenue growth of 17.1%, and its $138.3 million of revenue exceeded Wall Street’s estimates by 3.5%. Company management is currently guiding for a 10.1% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 11% over the next 12 months, a deceleration versus the last three years. Despite the slowdown, this projection is above average for the sector and implies the market sees some success for its newer products and services. Story Continues Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Customer Acquisition Efficiency The customer acquisition cost (CAC) payback period measures the months a company needs to recoup the money spent on acquiring a new customer. This metric helps assess how quickly a business can break even on its sales and marketing investments. Doximity is extremely efficient at acquiring new customers, and its CAC payback period checked in at 5.9 months this quarter. The company’s rapid recovery of its customer acquisition costs means it can attempt to spur growth by increasing its sales and marketing investments. Key Takeaways from Doximity’s Q1 Results We were impressed by how significantly Doximity blew past analysts’ revenue and EBITDA expectations this quarter. On the other hand, its revenue guidance for next year fell short of Wall Street's estimates and suggests a significant slowdown in demand. Overall, this was a weaker quarter. The stock traded down 18.2% to $47.80 immediately after reporting. Doximity underperformed this quarter, but does that create an opportunity to invest right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it’s free. View Comments
Doximity (NYSE:DOCS) Posts Better-Than-Expected Sales In Q1 But Stock Drops 18.2%
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...